A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer
Status:
Completed
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men
undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal
therapy cohort.